Navigation Links
Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company
Date:10/27/2008

KOBE, Japan, Oct. 27 /PRNewswire/ -- Carna Biosciences, Inc. ("Carna") announced on October 27, 2008, the signing of a Distribution Agreement with Shanghai Universal Biotech Company ("SUBC"). Under the terms of this Agreement, SUBC will become the exclusive distributor of Carna's Protein Kinases within China.

With China's emergence as a strong market opportunity, particularly in the life sciences, major biopharmaceutical companies have now established research and production facilities in Shanghai and other regions of China. These facilities seek and require goods to support their internal drug discovery programs. Carna is an established global provider of protein kinases used in the discovery and development of the important class of drugs known as kinase inhibitors. The Agreement with SUBC makes these products readily available to Chinese researchers via SUBC's strong distribution channels.

In addition to major biopharmaceutical presence, tax incentives provided by the Chinese government have provided a fertile environment for the establishment of bio-venture companies and CRO. The Agreement between Carna and SUBC, with its offices in the major cities of Shanghai and Beijing, is anticipated to lead to significantly increased sales opportunities for Carna and further establish its reputation as a global provider of protein kinases.

About Carna

Carna Biosciences, Inc. (http://www.carnabio.com/english/), founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, and providing drug discovery services to pharmaceutical companies using proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development. The products and services provided by Carna include kinase proteins, assay development services, kinase profiling and screening services, and crystallography products and services.

About SUBC

Shanghai Universal Biotech Company(http://www.univ-bio.com), founded in December 2004, is a Chinese distributor of biological reagents and experimental installations. The company provides antibody and reagent products as an agent of biological companies at home and abroad.
Contact:

Tomohisa Yamazaki, Manager

Corporate Planning

Carna Biosciences, Inc.

Phone: +81-78-302-7039

Fax: +81-78-302-6665

E-mail: ir-team@carnabio.com

URL: http://www.carnabio.com/english/


'/>"/>
SOURCE Carna Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
2. Isis Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
3. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
5. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
6. Pressure BioSciences, Inc. Provides Corporate Update
7. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
8. Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
9. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
10. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
11. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... The ... the organization’s history, it is offering its 2016 AAT Member Certification Qualification Course for ... The curriculum for the webinar, which will include a detailed review of hardware, software, ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Vice President for Public Policy for the National Organization for Rare Disorders (NORD). ... groups to ensure their voices are heard throughout the drug regulatory review process. ...
(Date:2/9/2016)... YORK , Feb. 9, 2016 This ... analyzes the current and future prospects of the market ... this report include companies engaged in the manufacture of ... an executive summary with a market snapshot providing the ... scope of this report. This section also provides the ...
(Date:2/9/2016)... -- Three-Year Initiative Supports Next Generation of Medical ... Life-Changing Camp Experiences ... the lives of children born with rare diseases, as well as ... is announcing a new initiative designed to positively affect the lives ... of rare disease care. --> To mark the company,s ...
Breaking Biology Technology:
(Date:1/25/2016)... Unisys Corporation (NYSE: UIS ) today announced the implementation ... New York City , to help U.S. ... the United States using passports that are ... of the system at Dulles last year. The system will ... 2016. --> pilot testing of the system at ...
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
Breaking Biology News(10 mins):